IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 617
EU - Europa 139
AS - Asia 45
AF - Africa 15
SA - Sud America 2
Totale 818
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 616
IT - Italia 40
IE - Irlanda 39
CN - Cina 27
TG - Togo 15
UA - Ucraina 15
IN - India 13
FR - Francia 12
DE - Germania 10
FI - Finlandia 7
GB - Regno Unito 5
SE - Svezia 4
TR - Turchia 4
AT - Austria 3
BR - Brasile 2
CA - Canada 1
ES - Italia 1
IR - Iran 1
NL - Olanda 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 818
Salva come PNG Salva come JPEG
Città #
Fairfield 69
Chandler 68
Ashburn 58
Dublin 39
Houston 38
Woodbridge 38
Cambridge 32
Seattle 30
Wilmington 27
Lomé 15
Ann Arbor 14
Dearborn 13
Ogden 12
Pune 12
Beijing 9
Princeton 9
Redmond 8
Los Angeles 7
Jacksonville 6
Udine 6
Helsinki 5
Cormons 4
Izmir 4
London 4
Zoppola 4
Codroipo 3
Cologne 3
New York 3
Vienna 3
Boardman 2
Deiva Marina 2
Des Moines 2
Leawood 2
Novara 2
Romans d'Isonzo 2
San Diego 2
Shenzhen 2
São Paulo 2
Vaestra Froelunda 2
Venice 2
Xi'an 2
Andover 1
Ardabil 1
Barking 1
Bhubaneswar 1
Coos Bay 1
Delft 1
Fayetteville 1
Frankfurt am Main 1
Fuzhou 1
Jinan 1
Krakow 1
Nanjing 1
New Albany 1
Norwalk 1
Novokuznetsk 1
Padova 1
Redwood City 1
Romano d'Ezzelino 1
San Mateo 1
Shenyang 1
Toronto 1
Treviso 1
Villafranca di Verona 1
Totale 590
Salva come PNG Salva come JPEG
Nome #
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 112
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 89
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 74
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 69
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 60
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 45
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 29
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 25
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 21
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 20
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 19
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 19
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 17
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 17
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 17
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 16
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 15
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 15
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 14
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 14
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 13
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 13
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 13
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 13
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 13
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 12
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 11
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 11
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 11
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 11
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 11
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 11
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 10
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 10
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 10
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 9
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 9
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 9
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 9
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 9
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 8
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 7
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 7
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 6
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 6
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 6
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 4
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 2
Totale 971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201924 0 0 0 0 0 0 0 0 0 0 16 8
2019/2020206 5 2 10 52 14 35 25 21 21 13 3 5
2020/2021127 3 6 19 16 8 11 28 11 8 5 7 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024230 31 19 11 4 39 40 21 15 19 31 0 0
Totale 971